These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

630 related items for PubMed ID: 16613687

  • 1. [Efficacy of rituximab-containing regimens on indolent B-cell lymphoma--a report of 34 cases].
    Xia ZJ, Wang FH, Huang HQ, Luo HY, Li YH, Lin TY, Jiang WQ, Guan ZZ.
    Ai Zheng; 2006 Apr; 25(4):490-4. PubMed ID: 16613687
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. [Comparison of rituximab plus CHOP regimen and CHOP regimen alone for treatment of newly diagnosed patients with diffuse large B-cell lymphoma].
    Wu HJ, Zhang QY, Chen DF, Guan XJ, Zhang BL, Ma J.
    Ai Zheng; 2005 Dec; 24(12):1498-502. PubMed ID: 16351800
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. [Clinical analysis of rituximab combined with chemotherapy in treating aggressive B-cell non-Hodgkin's lymphoma].
    Zhang HY, Lin TY, Jiang WQ, Zhang L, Huang HQ, Xia ZJ, Sun XF, He YJ, Guan ZZ.
    Ai Zheng; 2004 Dec; 23(12):1681-6. PubMed ID: 15601560
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. A pilot study of epratuzumab and rituximab in combination with cyclophosphamide, doxorubicin, vincristine, and prednisone chemotherapy in patients with previously untreated, diffuse large B-cell lymphoma.
    Micallef IN, Kahl BS, Maurer MJ, Dogan A, Ansell SM, Colgan JP, Geyer S, Inwards DJ, White WL, Habermann TM.
    Cancer; 2006 Dec 15; 107(12):2826-32. PubMed ID: 17099879
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. [Treatment effect of DICE regimen on patients with relapsed or refractory intermediate and high grade non-Hodgkin's lymphoma].
    Zhou SY, Shi YK, He XH, Zhang P, Dong M, Huang DZ, Yang JL, Zhang CG, Liu P, Yang S, Feng FY.
    Ai Zheng; 2005 Apr 15; 24(4):465-9. PubMed ID: 15820071
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. [Increased response rate with rituximab in relapsed and refractory follicular and mantle cell lymphomas -- results of a prospective randomized study of the German Low-Grade Lymphoma Study Group].
    Forstpointner R, Hänel A, Repp R, Hermann S, Metzner B, Pott C, Hartmann F, Rothmann F, Böck HP, Wandt H, Unterhalt M, Hiddemann W.
    Dtsch Med Wochenschr; 2002 Oct 25; 127(43):2253-8. PubMed ID: 12397539
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. [Prognostic analysis of patients with nasal-type NK/T-cell non-Hodgkin's lymphoma--a report of 93 cases].
    Pan ZH, Huang HQ, Lin XB, Xia YF, Xia ZJ, Peng YL, Cai QQ, Lin TY, Jiang WQ, Guan ZZ.
    Ai Zheng; 2005 Dec 25; 24(12):1493-7. PubMed ID: 16351799
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Fludarabine, cyclophosphamide, and rituximab for the treatment of patients with chronic lymphocytic leukemia or indolent non-Hodgkin lymphoma.
    Tam CS, Wolf M, Prince HM, Januszewicz EH, Westerman D, Lin KI, Carney D, Seymour JF.
    Cancer; 2006 Jun 01; 106(11):2412-20. PubMed ID: 16649223
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 32.